Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Impact of Major Vascular Complication Access Site Status on Mortality After Transfemoral Transcatheter Aortic Valve Replacement - Results From the FinnValve Registry

Lahtinen Asta; Juvonen Tatu; Mäkikallio Timo; Piuhola Jarkko; Biancari Fausto; Eskola Markku; Airaksinen Juhani; Husso Annastiina; Jalava Maina P.; Ahvenvaara Tuomas; Kinnunen Eeva-Maija; Valtola Antti; Laine Mika; Virtanen Marko; Niemelä Matti; Laakso Teemu; Maaranen Pasi; Moriyama Noriaki; Savontaus Mikko; Tauriainen Tuomas; Raivio Peter; Dahlbacka Sebastian

Impact of Major Vascular Complication Access Site Status on Mortality After Transfemoral Transcatheter Aortic Valve Replacement - Results From the FinnValve Registry

Lahtinen Asta
Juvonen Tatu
Mäkikallio Timo
Piuhola Jarkko
Biancari Fausto
Eskola Markku
Airaksinen Juhani
Husso Annastiina
Jalava Maina P.
Ahvenvaara Tuomas
Kinnunen Eeva-Maija
Valtola Antti
Laine Mika
Virtanen Marko
Niemelä Matti
Laakso Teemu
Maaranen Pasi
Moriyama Noriaki
Savontaus Mikko
Tauriainen Tuomas
Raivio Peter
Dahlbacka Sebastian
Katso/Avaa
Publisher's PDF (1.396Mb)
Lataukset: 

Japanese Circulation Society
doi:10.1253/circrep.CR-20-0007
URI
https://www.jstage.jst.go.jp/article/circrep/2/3/2_CR-20-0007/_article
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2022020818126
Tiivistelmä

Background: The aim of this study was to investigate the impact of anatomical site status and major vascular complication (MVC) severity on the outcome of transfemoral transcatheter aortic valve replacement (TF-TAVR).

Methods and Results: The FinnValve registry enrolled consecutive TAVR patients from 2008 to 2017. MVC was divided into 2 groups: non-access site-related MVC (i.e., MVC in aorta, aortic valve annulus or left ventricle); and access site-related MVC (i.e., MVC in iliac or femoral arteries). Severity of access site-related MVC was measured as units of red blood cell (RBC) transfusion. Of 1,842 patients who underwent TF-TAVR, 174 had MVC (9.4%; non-access site related, n=29; access site related, n=145). Patients with MVC had a significantly higher 3-year mortality than those without MVC (40.8% vs. 24.3%; HR, 2.01; 95% CI: 1.16-3.62). Adjusted 3-year mortality risk was significantly increased in the non-access site-related MVC group (mortality, 77.8%; HR, 4.30; 95% CI: 2.63-7.02), but not in the access site-related MVC group (mortality, 32.6%; HR, 1.38; 95% CI: 0.86-2.15). In the access site-related MVC group, only those with RBC transfusion ≥4 units had a significantly increased 3-year mortality risk (mortality, 51.8%; HR, 2.18; 95% CI: 1.19-3.89).

Conclusions: In patients undergoing TF-TAVR, MVC was associated with an increased 3-year mortality risk, incrementally correlating with anatomical site and bleeding severity.

Kokoelmat
  • Rinnakkaistallenteet [19207]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste